Item 2.02. Results of Operations and Financial Condition.

The Corporate Presentation (as defined below) of Pear Therapeutics, Inc. (the "Company") is attached to this Current Report on Form 8-K as Exhibit 99.1 and references the Company's previously disclosed projected revenue of $4.0 million for fiscal year 2021.

The information in this Item 2.02 and the attached Exhibit 99.1 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure.

The Company from time to time presents at various industry and other conferences and provides summary business information. A copy of the slide presentation that will be used by representatives of the Company in connection with such presentations (the "Corporate Presentation") is attached to this Current Report on Form 8-K as Exhibit 99.1. The Corporate Presentation is current as of January 11, 2022 and the Company disclaims any obligation to correct or update this material in the future.

The information in this Item 7.01 and the attached Exhibit 99.1 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Corporate Presentation current as of January 11, 2022 .

© Edgar Online, source Glimpses